473 related articles for article (PubMed ID: 32022846)
21. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
Strober BE; Bissonnette R; Fiorentino D; Kimball AB; Naldi L; Shear NH; Goyal K; Fakharzadeh S; Calabro S; Langholff W; You Y; Galindo C; Lee S; Lebwohl MG
J Am Acad Dermatol; 2016 May; 74(5):851-61.e4. PubMed ID: 26853180
[TBL] [Abstract][Full Text] [Related]
22. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
Al-Mutairi N; Nour T
Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR.
Alabas OA; Mason KJ; Yiu ZZN; Hampton PJ; Reynolds NJ; Owen CM; Bewley A; Laws PM; Warren RB; Lunt M; Smith CH; Griffiths CEM;
Br J Dermatol; 2023 Apr; 188(5):618-627. PubMed ID: 36763783
[TBL] [Abstract][Full Text] [Related]
24. A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study.
de Vries AC; Thio HB; de Kort WJ; Opmeer BC; van der Stok HM; de Jong EM; Horvath B; Busschbach JJ; Nijsten TE; Spuls PI
Br J Dermatol; 2017 Mar; 176(3):624-633. PubMed ID: 27416891
[TBL] [Abstract][Full Text] [Related]
25. Biologics combined with conventional systemic agents for the treatment of children with severe psoriasis. Real-life data from the BiPe cohorts and a practice survey among French and Italian pediatric dermatologists.
Mahé E; Beauchet A; Hadj-Rabia S; Mazereeuw-Hautier J; Mallet S; Phan A; Severino-Freire M; Boralevi F; Aubert H; Barthélémy H; Girard C; Martin L; Piram M; Barbarot S; Balguerie X; Zitouni J; Phan C; Di Lernia V;
Dermatol Ther; 2022 Nov; 35(11):e15828. PubMed ID: 36107157
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
27. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort.
Dalaker M; Bonesrønning JH
J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):277-82. PubMed ID: 19207642
[TBL] [Abstract][Full Text] [Related]
28. Combination Therapy of Etanercept and Fumarates versus Etanercept Monotherapy in Psoriasis: A Randomized Exploratory Study.
van Bezooijen JS; Balak DM; van Doorn MB; Looman CW; Schreurs MW; Koch BC; van Gelder T; Prens EP
Dermatology; 2016; 232(4):407-14. PubMed ID: 27576483
[TBL] [Abstract][Full Text] [Related]
29. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
[TBL] [Abstract][Full Text] [Related]
30. Association Between Quality of Life and Improvement in Psoriasis Severity and Extent in Pediatric Patients.
Bruins FM; Bronckers IMGJ; Groenewoud HMM; van de Kerkhof PCM; de Jong EMGJ; Seyger MMB
JAMA Dermatol; 2020 Jan; 156(1):72-78. PubMed ID: 31774449
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.
Inzinger M; Heschl B; Weger W; Hofer A; Legat FJ; Gruber-Wackernagel A; Tilz H; Salmhofer W; Quehenberger F; Wolf P
Br J Dermatol; 2011 Sep; 165(3):640-5. PubMed ID: 21564068
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT.
Maul JT; Djamei V; Kolios AGA; Meier B; Czernielewski J; Jungo P; Yawalkar N; Mainetti C; Laffitte E; Spehr C; Anliker M; Streit M; Augustin M; Rustenbach S; Conrad C; Hafner J; Boehncke WH; Borradori L; Gilliet M; Itin P; French LE; Häusermann P; Navarini AA
Dermatology; 2016; 232(6):640-647. PubMed ID: 28076860
[TBL] [Abstract][Full Text] [Related]
33. Risk of Infection in Children With Psoriasis Receiving Treatment With Ustekinumab, Etanercept, or Methotrexate Before and After Labeling Expansion.
Schneeweiss MC; Savage TJ; Wyss R; Jin Y; Schoder K; Merola JF; Sidbury R; Oduol T; Schneeweiss S; Glynn RJ
JAMA Dermatol; 2023 Mar; 159(3):289-298. PubMed ID: 36753234
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study).
Orsini D; Caldarola G; Dattola A; Campione E; Bernardini N; Frascione P; De Simone C; Richetta AG; Galluzzo M; Skroza N; Assorgi C; Amore E; Falco GM; Gaeta Shumak R; Artosi F; Maretti G; Potenza C; Bianchi L; Pellacani G; Peris K; Bonifati C; Graceffa D
J Dermatolog Treat; 2024 Dec; 35(1):2319304. PubMed ID: 38413097
[No Abstract] [Full Text] [Related]
35. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
Warren RB; Gooderham M; Burge R; Zhu B; Amato D; Liu KH; Shrom D; Guo J; Brnabic A; Blauvelt A
J Am Acad Dermatol; 2020 May; 82(5):1138-1149. PubMed ID: 31884091
[TBL] [Abstract][Full Text] [Related]
36. Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India.
Kaur I; Dogra S; De D; Kanwar AJ
Pediatr Dermatol; 2008; 25(2):184-8. PubMed ID: 18429775
[TBL] [Abstract][Full Text] [Related]
37. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
38. Etanercept treatment for children and adolescents with plaque psoriasis.
Paller AS; Siegfried EC; Langley RG; Gottlieb AB; Pariser D; Landells I; Hebert AA; Eichenfield LF; Patel V; Creamer K; Jahreis A;
N Engl J Med; 2008 Jan; 358(3):241-51. PubMed ID: 18199863
[TBL] [Abstract][Full Text] [Related]
39. Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis.
Menting SP; Sitaram AS; Bonnerjee-van der Stok HM; de Rie MA; Hooft L; Spuls PI
Br J Dermatol; 2014 Oct; 171(4):875-83. PubMed ID: 24673245
[TBL] [Abstract][Full Text] [Related]
40. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
Talamonti M; Galluzzo M; Bernardini N; Caldarola G; Persechino S; Cantoresi F; Egan CG; Potenza C; Peris K; Bianchi L
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1737-1744. PubMed ID: 29776016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
